MX352338B - Anticuerpos neutralizantes del virus de la influenza a y usos de estos. - Google Patents
Anticuerpos neutralizantes del virus de la influenza a y usos de estos.Info
- Publication number
- MX352338B MX352338B MX2014000749A MX2014000749A MX352338B MX 352338 B MX352338 B MX 352338B MX 2014000749 A MX2014000749 A MX 2014000749A MX 2014000749 A MX2014000749 A MX 2014000749A MX 352338 B MX352338 B MX 352338B
- Authority
- MX
- Mexico
- Prior art keywords
- influenza
- antibodies
- subtype
- epitopes
- neutralizing anti
- Prior art date
Links
- 206010022000 influenza Diseases 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 title 1
- 230000003472 neutralizing effect Effects 0.000 title 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 2
- 101710154606 Hemagglutinin Proteins 0.000 abstract 1
- 241000712431 Influenza A virus Species 0.000 abstract 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 abstract 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 abstract 1
- 101710176177 Protein A56 Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000000185 hemagglutinin Substances 0.000 abstract 1
- 208000037797 influenza A Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 210000004180 plasmocyte Anatomy 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 239000013638 trimer Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere a anticuerpos y fragmentos de unión a antígeno de éstos, que se unen específicamente a un epítopo en la región del tallo de un trímero de hemaglutinina de la influenza A y neutralizan un subtipo del grupo 1 y un subtipo del grupo 2 del virus de la influenza A; ácidos nucleicos que codifican células B inmortalizadas y células plasmáticas individuales cultivadas que producen, y epítopos que se unen a tales anticuerpos y fragmentos de anticuerpo; además, el uso de los anticuerpos, fragmentos de anticuerpo y epítopos en métodos de selección, así como en el diagnóstico, tratamiento y prevención de la infección por el virus de la influenza A.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2011/002329 WO2013011347A1 (en) | 2011-07-18 | 2011-07-18 | Neutralizing anti-influenza a virus antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014000749A MX2014000749A (es) | 2014-05-07 |
| MX352338B true MX352338B (es) | 2017-11-17 |
Family
ID=44993618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014000749A MX352338B (es) | 2011-07-18 | 2011-07-18 | Anticuerpos neutralizantes del virus de la influenza a y usos de estos. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US9587010B2 (es) |
| EP (3) | EP3418300B1 (es) |
| JP (1) | JP6035332B2 (es) |
| CN (1) | CN103717617B (es) |
| AU (1) | AU2011373387B2 (es) |
| CA (1) | CA2841551C (es) |
| DK (2) | DK3418300T3 (es) |
| ES (2) | ES2732552T3 (es) |
| HR (2) | HRP20190714T1 (es) |
| HU (2) | HUE051756T2 (es) |
| LT (2) | LT2734545T (es) |
| MX (1) | MX352338B (es) |
| PL (2) | PL2734545T3 (es) |
| SI (2) | SI2734545T1 (es) |
| WO (1) | WO2013011347A1 (es) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
| EP2318832B1 (en) | 2008-07-15 | 2013-10-09 | Academia Sinica | Glycan arrays on ptfe-like aluminum coated glass slides and related methods |
| US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| US10338069B2 (en) | 2010-04-12 | 2019-07-02 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
| KR101915647B1 (ko) | 2010-05-10 | 2018-11-06 | 아카데미아 시니카 | 항-인플루엔자 활성을 가진 자나미비르 포스포네이트 동족체 및 인플루엔자 바이러스의 오셀타미비르 감수성을 확인하는 방법 |
| CN107417789A (zh) * | 2011-07-18 | 2017-12-01 | 生物医学学会 | 中和抗甲型流感病毒抗体及其用途 |
| JP6035332B2 (ja) | 2011-07-18 | 2016-11-30 | インスティテュート・フォー・リサーチ・イン・バイオメディシンＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｒｅｓｅａｒｃｈ Ｉｎ Ｂｉｏｍｅｄｉｃｉｎｅ | Ａ型インフルエンザウイルス中和抗体及びその使用法 |
| US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
| US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
| WO2014031498A1 (en) | 2012-08-18 | 2014-02-27 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
| US9547009B2 (en) | 2012-08-21 | 2017-01-17 | Academia Sinica | Benzocyclooctyne compounds and uses thereof |
| PE20150945A1 (es) | 2012-11-13 | 2015-06-26 | Genentech Inc | Anticuerpos de antihemaglutinina y metodos de uso |
| KR20140118682A (ko) | 2013-03-29 | 2014-10-08 | (주)셀트리온 | 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물 |
| WO2014210397A1 (en) | 2013-06-26 | 2014-12-31 | Academia Sinica | Rm2 antigens and use thereof |
| EP3013347B1 (en) | 2013-06-27 | 2019-12-11 | Academia Sinica | Glycan conjugates and use thereof |
| US9782476B2 (en) | 2013-09-06 | 2017-10-10 | Academia Sinica | Human iNKT cell activation using glycolipids with altered glycosyl groups |
| KR102501920B1 (ko) * | 2013-10-02 | 2023-02-20 | 메디뮨 엘엘씨 | 중화 항-인플루엔자 a 항체 및 이의 용도 |
| US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| KR20160104727A (ko) | 2014-01-16 | 2016-09-05 | 아카데미아 시니카 | 암의 치료 및 검출을 위한 조성물 및 방법 |
| EP3119804A2 (en) | 2014-03-19 | 2017-01-25 | Dana-Farber Cancer Institute, Inc. | Immunogenetic restriction on elicitation of antibodies |
| CN106415244B (zh) | 2014-03-27 | 2020-04-24 | 中央研究院 | 反应性标记化合物及其用途 |
| EP3137487B1 (en) | 2014-05-01 | 2021-03-03 | Indian Institute of Science | Polypeptides for generating anti-influenza antibodies and uses thereof |
| US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
| KR20170003720A (ko) | 2014-05-27 | 2017-01-09 | 아카데미아 시니카 | 항-ｃｄ20 글리코항체 및 이의 용도 |
| KR20230033737A (ko) * | 2014-05-27 | 2023-03-08 | 아카데미아 시니카 | 증진된 항체 효능을 위한 범용 당형태에 관한 조성물 및 방법 |
| KR102512592B1 (ko) | 2014-05-27 | 2023-03-21 | 아카데미아 시니카 | 항-ｈｅｒ2 글리코항체 및 이의 용도 |
| CN106714829A (zh) | 2014-05-28 | 2017-05-24 | 中央研究院 | 抗TNF‑α醣抗体及其用途 |
| CN113563462B (zh) | 2014-07-15 | 2024-08-13 | 免疫医疗有限责任公司 | 中和抗乙型流感抗体及其用途 |
| WO2016040369A2 (en) | 2014-09-08 | 2016-03-17 | Academia Sinica | HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS |
| TWI702229B (zh) | 2014-12-19 | 2020-08-21 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
| US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
| US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| TWI736523B (zh) | 2015-01-24 | 2021-08-21 | 中央研究院 | 新穎聚醣結合物及其使用方法 |
| EP3253411A1 (en) | 2015-02-05 | 2017-12-13 | Janssen Vaccines & Prevention B.V. | Binding molecules directed against influenza hemagglutinin and uses thereof |
| GB201502137D0 (en) | 2015-02-09 | 2015-03-25 | Ucl Business Plc | Treatment |
| JP6960856B2 (ja) * | 2015-04-08 | 2021-11-05 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | ヒト化インフルエンザモノクローナル抗体およびその使用方法 |
| PL3303384T3 (pl) | 2015-06-01 | 2022-01-03 | Medimmune, Llc | Neutralizujące cząsteczki wiążące przeciw grypie i ich zastosowania |
| US10513553B2 (en) | 2015-11-13 | 2019-12-24 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| JP2019502715A (ja) | 2016-01-13 | 2019-01-31 | メディミューン，エルエルシー | Ａ型インフルエンザを治療する方法 |
| JP7104629B2 (ja) | 2016-02-24 | 2022-07-21 | ビステラ， インコーポレイテッド | インフルエンザウイルスに対する抗体分子の製剤 |
| AU2017231749A1 (en) | 2016-03-08 | 2018-09-20 | Academia Sinica | Methods for modular synthesis of N-glycans and arrays thereof |
| WO2017192589A1 (en) * | 2016-05-02 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to influenza ha and their use and identification |
| SG10202011021XA (en) * | 2016-05-05 | 2020-12-30 | Univ Pennsylvania | Dna monoclonal antibodies targeting influenza virus |
| TWI764917B (zh) | 2016-08-22 | 2022-05-21 | 醣基生醫股份有限公司 | 抗體、結合片段及使用方法 |
| WO2018038096A1 (ja) * | 2016-08-23 | 2018-03-01 | 国立大学法人東京大学 | モノクローナル抗体又はその抗原結合フラグメント及びその使用 |
| CN107868121B (zh) * | 2016-09-28 | 2021-03-16 | 中国医学科学院病原生物学研究所 | H3亚型流感病毒血凝素特异性保守表位、其抗体及其应用 |
| CA3051377A1 (en) | 2017-01-27 | 2018-08-02 | National Research Council Of Canada | Hemagglutinin-specific antibodies and uses thereof |
| CA3132521A1 (en) | 2019-03-25 | 2020-10-01 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| US20220340644A1 (en) * | 2019-09-19 | 2022-10-27 | Duke University | Influenza neutralizing antibodies and their uses |
| EP4031558A4 (en) * | 2019-09-20 | 2023-05-31 | Academia Sinica | CHIMERIC HEMAGGLUTININ PROTEIN AND VACCINE COMPOSITION COMPRISING THEM |
| JP2023506156A (ja) | 2019-12-11 | 2023-02-15 | ビステラ， インコーポレイテッド | インフルエンザを処置または予防するための組成物および方法 |
| CA3237090A1 (en) * | 2021-11-05 | 2023-05-11 | Dana-Farber Cancer Institute, Inc. | Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof |
| CN117430664B (zh) * | 2023-10-24 | 2024-04-09 | 暨南大学附属第六医院(东莞市东部中心医院) | 一种甲型流感病毒t细胞抗原表位肽及其应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB819376A (en) | 1956-10-20 | 1959-09-02 | Colne Switchgear K & W Ltd | Improvements in electro-magnetic overload units for electrical apparatus |
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3766162A (en) | 1971-08-24 | 1973-10-16 | Hoffmann La Roche | Barbituric acid antigens and antibodies specific therefor |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| PT859841E (pt) | 1995-08-18 | 2002-11-29 | Morphosys Ag | Bibliotecas de proteinas/ (poli) peptidos |
| WO1998057993A1 (en) | 1997-06-19 | 1998-12-23 | The Regents Of The University Of California | Secretory immunoglobulin produced by single cells and methods for making and using same |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| US8101553B1 (en) | 2000-02-22 | 2012-01-24 | Medical & Biological Laboratories Co., Ltd. | Antibody library |
| AU2003251809A1 (en) | 2002-07-11 | 2004-02-02 | The General Hospital Corporation | Polynucleotide and polypeptide fat metabolism regulators and uses thereof |
| WO2004076677A2 (en) | 2003-02-26 | 2004-09-10 | Institute For Research In Biomedicine | Monoclonal antibody production by ebv transformation of b cells |
| CN1756562A (zh) * | 2003-03-07 | 2006-04-05 | 麦克公司 | 流感病毒疫苗 |
| CN103446582A (zh) | 2003-08-11 | 2013-12-18 | 财团法人阪大微生物病研究会 | 包含诱导粘膜免疫的佐剂的新型疫苗 |
| WO2006124269A2 (en) | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders |
| AR058104A1 (es) | 2005-10-21 | 2008-01-23 | Novartis Ag | Compuestos organicos |
| TWI477602B (zh) | 2006-02-09 | 2015-03-21 | Educational Foundation Jichi Medical Univ | Novel viral vector |
| WO2007134327A2 (en) | 2006-05-15 | 2007-11-22 | Sea Lane Biotechnologies, Llc. | Neutralizing antibodies to influenza viruses |
| MY170607A (en) | 2006-09-07 | 2019-08-20 | Crucell Holland Bv | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
| CN101541832B (zh) * | 2006-09-07 | 2014-11-12 | 克鲁塞尔荷兰公司 | 能中和流感病毒h5n1的人结合分子及其应用 |
| PT2069403E (pt) | 2006-10-02 | 2014-07-18 | Regeneron Pharma | Anticorpos humanos com elevada afinidade para o receptor de il-4 humana |
| AU2007325872B2 (en) | 2006-11-08 | 2012-12-13 | Macrogenics West, Inc. | TES7 and antibodies that bind thereto |
| EP1925318A1 (en) | 2006-11-20 | 2008-05-28 | Paul-Ehrlich-Institut | Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| GB0700133D0 (en) | 2007-01-04 | 2007-02-14 | Humabs Llc | Human cytomegalovirus neutralising antibodies and use thereof |
| CN102046654A (zh) | 2007-03-13 | 2011-05-04 | 胡马斯有限公司 | 针对甲型流感病毒h5n1株系的抗体 |
| EA034733B1 (ru) | 2008-01-21 | 2020-03-13 | Медикаго Инк. | Нуклеиновая кислота для увеличенной экспрессии гемагглютинина вируса гриппа в растении и ее применение |
| ITTO20080204A1 (it) | 2008-03-17 | 2009-09-18 | Pomona Biotechnologies Llc | Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a |
| CN102216327A (zh) | 2008-07-25 | 2011-10-12 | 生物医学研究所 | 中和抗甲型流感病毒抗体及其用途 |
| US9347043B2 (en) | 2008-10-22 | 2016-05-24 | Institute For Research In Biomedicine | Methods for producing antibodies from plasma cells |
| EP2413962A1 (en) | 2009-03-30 | 2012-02-08 | Mount Sinai School of Medicine | Influenza virus vaccines and uses thereof |
| NZ597401A (en) | 2009-06-24 | 2013-09-27 | Medicago Inc | Chimeric influenza virus-like particles comprising hemagglutinin |
| JP6035332B2 (ja) | 2011-07-18 | 2016-11-30 | インスティテュート・フォー・リサーチ・イン・バイオメディシンＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｒｅｓｅａｒｃｈ Ｉｎ Ｂｉｏｍｅｄｉｃｉｎｅ | Ａ型インフルエンザウイルス中和抗体及びその使用法 |
-
2011
- 2011-07-18 JP JP2014520738A patent/JP6035332B2/ja active Active
- 2011-07-18 EP EP18180926.0A patent/EP3418300B1/en active Active
- 2011-07-18 PL PL11784765T patent/PL2734545T3/pl unknown
- 2011-07-18 SI SI201131700T patent/SI2734545T1/sl unknown
- 2011-07-18 CN CN201180072356.0A patent/CN103717617B/zh active Active
- 2011-07-18 LT LTEP11784765.7T patent/LT2734545T/lt unknown
- 2011-07-18 WO PCT/IB2011/002329 patent/WO2013011347A1/en active Application Filing
- 2011-07-18 MX MX2014000749A patent/MX352338B/es active IP Right Grant
- 2011-07-18 AU AU2011373387A patent/AU2011373387B2/en active Active
- 2011-07-18 DK DK18180926.0T patent/DK3418300T3/da active
- 2011-07-18 PL PL18180926T patent/PL3418300T3/pl unknown
- 2011-07-18 DK DK11784765.7T patent/DK2734545T3/en active
- 2011-07-18 US US14/233,719 patent/US9587010B2/en active Active
- 2011-07-18 HU HUE18180926A patent/HUE051756T2/hu unknown
- 2011-07-18 LT LTEP18180926.0T patent/LT3418300T/lt unknown
- 2011-07-18 EP EP20200200.2A patent/EP3812397A1/en active Pending
- 2011-07-18 CA CA2841551A patent/CA2841551C/en active Active
- 2011-07-18 SI SI201131938T patent/SI3418300T1/sl unknown
- 2011-07-18 ES ES11784765T patent/ES2732552T3/es active Active
- 2011-07-18 EP EP11784765.7A patent/EP2734545B1/en active Active
- 2011-07-18 ES ES18180926T patent/ES2841899T3/es active Active
- 2011-07-18 HU HUE11784765A patent/HUE044089T2/hu unknown
-
2017
- 2017-01-20 US US15/411,677 patent/US20170204167A1/en not_active Abandoned
-
2018
- 2018-11-01 US US16/178,497 patent/US10815294B2/en active Active
-
2019
- 2019-04-16 HR HRP20190714TT patent/HRP20190714T1/hr unknown
-
2020
- 2020-12-10 HR HRP20201975TT patent/HRP20201975T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014000749A (es) | Anticuerpos neutralizantes del virus de la influenza a y usos de estos. | |
| MX2011000767A (es) | Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos. | |
| PH12018500916A1 (en) | Antibody neutralizing human respiratory syncytial virus | |
| ZA201807467B (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
| MY166282A (en) | Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses | |
| EA032929B1 (ru) | Нейтрализующее вирус иммунодефицита человека антитело и способы его применения | |
| PH12017500727A1 (en) | Modified virus-like particles of cmv | |
| WO2013059524A3 (en) | Antibodies directed against influenza | |
| MX356337B (es) | Anticuerpos contra csf-1r humano y sus usos. | |
| PH12021550521A1 (en) | Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof | |
| UA116999C2 (uk) | Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить | |
| WO2011092593A3 (en) | Hiv-1 neutralizing antibodies and uses thereof | |
| MX2019007921A (es) | Nuevos agentes de union a ha. | |
| NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
| MY177098A (en) | Novel anti-human tslp receptor antibody | |
| EP3492101A3 (en) | Agents for influenza neutralization | |
| BR112014023063A2 (pt) | anticorpos que neutralizam rsv, mpv e pvm e usos dos mesmos | |
| EA201400216A1 (ru) | Консервирование биологических продуктов, в частности вакцин, с применением вакуума | |
| WO2016075546A3 (en) | Antibodies that neutralize ebola virus and uses thereof | |
| WO2014165028A8 (en) | Antibodies specific to a novel epitope on cemx of human membrane-bound ige and uses thereof in treating ige-mediated diseases | |
| TN2011000028A1 (en) | Neutralizing anti-influenza a virus antibodies and uses therof | |
| TN2013000068A1 (en) | Anti-vegfr-3 antibody compositions | |
| EA201891048A1 (ru) | Антитело, нейтрализующее респираторно-синцитиальный вирус человека | |
| WO2015147754A8 (en) | Chimerization and characterization of a monoclonal antibody with potent neutralizing activity across multiple influenza a h5n1 clades |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |